Leading layer-1 blockchain Injective has integrated Klaytn to fully scale the cross-chain interoperability of its network. In a Monday blog post, Injective confirmed the integration, describing it as a historic win for the emerging web3 space. According to the firm, the collaboration will ensure the utilization of KLAY and INJ for several cross-chain oriented programs. Don’t forget that KLAY is the native token of Klaytn and INJ is for Injective.
By allowing the utilization of both assets for cross-chain initiatives, the two firms aim to foster a more composable ecosystem for their respective communities. Therefore, users can now transfer and use KLAY and INJ across every dApp running on both networks. With this, the use cases of the assets will be expanded. Likewise, the development will also pave the way for the two blockchains to grow beyond their current state.
Injective sees its integration of Klaytn as a huge feat in its bid to foster the expansion of the IBC network. The firm hopes to cement its status as the fastest L1 in the evolving blockchain sector. It is optimistic that its collaboration with Klaytn will help it become the project to beat among its contemporaries. Likewise, it plans to leverage the integration to improve its value proposition, becoming one of the most interoperable networks.
Injective has become a household name in the industry, creating easy access to notable layer 1 blockchains, bridging communities, and activating new opportunities for web3 development. With its latest integration, the firm seeks to onboard more users to its ecosystem. More so, it wants to set a precedence on how blockchain firms can collaborate to foster the development of a truly decentralized ecosystem.
Injective launches “Helix Institutional”
In August, Injective unveiled Helix Institutional to aid decentralized trading. It designed the solution to run on its network as a trading portal for financial organizations. Helix allows users to execute derivatives trades. More so, it helps to onboard a wide variety of financial firms into the on-chain trading arena. With this, the Injective ecosystem will be able to gain huge capital inflow. Nevertheless, it is worth noting that firms using this solution must trade in compliance with regulatory standards.